Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRS study
ISRCTN56178790Phase 2Completed
- Sponsor
- Wygrajmy Zdrowie
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in testicular cancer and germ cell tumor (GCT), sponsored by Wygrajmy Zdrowie. Primary endpoint: Progression-free survival. Started Mar 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
testicular cancergerm cell tumor (GCT)
Beyond the preview
Go deeper on ISRCTN56178790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN56178790.